Form 4: Curis Inc. Director Greenacre Receives Stock Option Grant Following Shareholder Approval

Director Martyn D Greenacre received a stock option grant for 4,250 shares of Curis Inc. following shareholder approval of the company's Fifth Amended and Restated 2010 Stock Incentive Plan.

Summary

• Martyn D Greenacre, a director of Curis Inc., received a stock option grant on May 21, 2024.
• The grant is for 4,250 shares of Curis Inc. common stock.
• The exercise price of the option is $11.62 per share.
• The option vests on January 20, 2025, and expires on January 19, 2034.
• The grant was contingent upon shareholder approval of Curis's Fifth Amended and Restated 2010 Stock Incentive Plan, which was obtained on May 21, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and the shareholder approval removes a potential hurdle. It indicates confidence in the company's future.

Positives

• The stock option grant aligns the director's interests with those of the shareholders.
• Shareholder approval of the Fifth Amended and Restated 2010 Stock Incentive Plan allows for the issuance of these options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their directors and officers.
• The size of the grant is typical for a director at a company of Curis's size and stage of development.

Stakeholder Impact

• Shareholders may view the option grant positively as it aligns the director's interests with the company's performance.
• Employees may see this as a positive sign of the company's commitment to incentivizing its leadership.

Key Dates